Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4403 Ki-67 index cut-off values and survival prognostication in neuroendocrine neoplasms: Machine learning-based insights

Introduction: The current grading system for gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) is based on Ki-67 index and/or mitotic rate. By definition, high-grade NEN (neuroendocrine tumour grade 3 [NET G3] and neuroendocrine carcinoma [NEC]) have a Ki-67 >20%, while NET G1 have a Ki-67

Conference:

Presenting Author:

Authors: Melhorn P, Berchtold L, Mazal P, Raderer M, Kiesewetter B,

Keywords: neuroendocrine neoplasm, prognosis, ki-67 index,

#1554 Combination of Lanreotide Autogel and Temozolomide in Patients with Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) - A Pilot-Study

Introduction: Therapeutic options for patients with advanced progressive GEP-NET are still limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Raderer M

Authors: Raderer M, Hörsch D, Lahner H, Rinke A, Denecke T,

Keywords: GEP-NET, Lanreotide, Temozolomide,

#1495 Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis

Introduction: Everolimus (EVE) demonstrated progression-free survival (PFS) benefit of 7.1 months compared to placebo in the phase 3 RADIANT-4 study in patients (pts) with advanced, well-differentiated, progressive, nonfunctional NET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Singh S

Authors: Singh S, Carnaghi C, Buzzoni R, Raderer M, Lahner H,

Keywords: Everolimus, progression-free survival, gastrointestinal NET,

#1211 Lack of Efficacy of Anthracycline-Containing Second Line Chemotherapy in Patients with GI-NEC After Cisplatin-Based Treatment

Introduction: Little is known about optimal 2nd-line treatment in patients with GI-NEC failing cisplatin-based therapy.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Kiesewetter B, Koparek O, Mayerhoefer M, Niederle B, Raderer M,

Keywords: GI-NEC,

#1194 Chromogranin A (CgA) and PFS Outcomes in Lanreotide Autogel (LAN) in Patients with Metastatic Enteropancreatic (EP-) NETs: Data from the CLARINET Study

Introduction: The CLARINET study showed LAN 120 mg prolonged PFS vs. placebo (PBO) in patients with metastatic EP-NETs.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Caplin M, Pavel M, Cwikla J, Phan A, Raderer M,

Keywords: lanreotide, biomarker,